检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:万佳蔚[1,2] 沈洪远[2] 黄红宇[2] 韩志君[2] 严子禾[2] 高明珠[2] 黄新祥[1]
机构地区:[1]江苏大学基础医学与医学技术学院,江苏镇江212013 [2]无锡市第二人民医院检验科,江苏无锡214002
出 处:《临床与病理杂志》2015年第1期43-47,共5页Journal of Clinical and Pathological Research
基 金:无锡市医院管理中心医学科技项目(YGZXQ1310)~~
摘 要:目的:评价非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的外周静脉血循环肿瘤细胞(c irculating tumor cel l s,CTC)计数的临床应用价值。方法:收集2013年1月~2013年12月无锡市第二人民医院诊断的50例NSCLC作为研究对象,同时收集良性肺部疾病患者35例及28例体检健康者。采集上述各研究组静脉血标本,检测静脉血CTC的数量,≥8.7单位判定为阳性。分析CTC计数与患者年龄、性别、病理类型及临床分期之间的关系。结果:NSCLC患者CTC计数显著高于良性肺部疾病对照组和健康对照组。NSCLC患者外周血中CTC与患者性别、年龄、病理类型无明显关系(P〉0.05),CTC数值随着肿瘤临床分期递进而增加(P〈0.01)。结论:NSCLC的CTC计数与患者临床特征具有一定相关性,可初步反映患者的疾病状态。Objective: To evaluate the clinical value of circulating tumor cells (CTC) count in peripheral venous blood of patients with non-small cell lung carcinoma (NSCLC). Methods: Totally S0 patients with NSCLC in Wuxi No. 2 people's Hospital were selected for study from January 2013 to December 2013, 35 patients with lung benign tumor and 28 normal volunteers were selected as the control groups. CTC collected from 3 mL venous blood of all people above were counted. Patients with 8.7 units or more CTC were judged to be positive. The relationship between the positive rate of CTC and the age, sex, pathological type and clinical stage was analyzed. Results: CTC count was significantly higher in NSCLC patients than in benign lung patients and healthy controls. CTC count in NSCLC patients was rarely related to the sex, age or the pathological type (P〉0.05) and was dosely related to clinical stage (P〈0.01). Among NSCLC patients, CTC count significantly increased along with tumor progression. Conclusion: The progression of patients with non-small-cell lung carcinoma was associated with the level of CTC count which can reflect the status of the patients to some extent.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145